7/103 sources · 3 publishersUpdated Oct 27, 06:29 UTC
AstraZeneca pushes PACIFIC-9 lung cancer trial readout to first half of 2027
AstraZeneca announced that the high‑level data readout for the PACIFIC‑9 Phase 3 trial, which tests durvalumab with monalizumab or oleclumab in unresectable Stage III non‑small cell lung cancer, has been moved to the first half of 2027. The change delays the original schedule of the second half of 2026 and reflects the event‑driven nature of the study. Enrollment in the trial is now complete.
Why it matters
The later readout postpones any potential regulatory filing and market launch timeline for the combination therapy, extending the period of uncertainty for investors in both AstraZeneca and Innate Pharma.
Key facts
- 1Enrollment in the PACIFIC‑9 trial is complete. stocktitan.net
- 2The expected high‑level data readout has been shifted to the first half of 2027. stocktitan.net
- 3The readout was previously expected in the second half of 2026. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.